GOSS Research and Charts

GOSS - Gossamer Bio Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2024-08-12 (Delayed quote data 2025-07-11)

Last 1.36	Change ⇓ 0.00 (0.00%)	Volume 695,693
	Open 1.34	High 1.40	Low 1.34

8EMA (Daily) 1.30	40EMA (Daily) 1.23	50EMA (Daily) 1.22	STO (Daily) 40.000	MACD Hist (Daily) 0.002
8EMA (Weekly) 1.262	40EMA (Weekly) 1.11	50EMA (Weekly) 1.12	STO (Weekly) 79.510	MACD Hist (Weekly) 0.040


Company Profile
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH(pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.